2. Apoptosis
  3. Apoptosis
  4. Anticancer agent 317

Anticancer agent 317, a Chidamide (HY-109015) derivative, is an apoptosis inducer. Anticancer agent 317 inhibits colony formation, migration, adhesion, invasion, tumor growth, and angiogenesis. Anticancer agent 317 can be used for the research of breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Anticancer agent 317

Anticancer agent 317 Chemische Struktur

CAS. Nr. : 3117779-13-9

Größe Verfügbarkeit
50 mg   Angebot einholen  
100 mg   Angebot einholen  
250 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 317 Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Anticancer agent 317, a Chidamide (HY-109015) derivative, is an apoptosis inducer. Anticancer agent 317 inhibits colony formation, migration, adhesion, invasion, tumor growth, and angiogenesis. Anticancer agent 317 can be used for the research of breast cancer[1].

In Vitro

Anticancer agent 317 (Compound 6e) potently and selectively inhibits proliferation of MDA-MB-231 breast cancer cells with an IC50 of 0.10 μM[1].
Anticancer agent 317 (0.025-0.1 μM; 24 h) dose-dependently inhibits long-term colony formation of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.025 μM[1].
Anticancer agent 317 (0.025-0.1 μM; 48 h) dose-dependently induces apoptosis in MDA-MB-231 breast cancer cells, with the highest level of apoptosis observed at 0.1 μM[1].
Anticancer agent 317 (0.01-0.04 μM; 24 h) dose-dependently inhibits adhesion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM[1].
Anticancer agent 317 (0.01-0.04 μM; 24-48 h) dose-dependently inhibits invasion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM[1].
Anticancer agent 317 (0.025-0.1 μM) dose-dependently inhibits angiogenesis and tumor growth in a chicken embryo CAM model of breast cancer, with the 0.1 μM dose reducing tumor weight to 8.33 mg and angiogenesis to 51.79% of control levels[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 317 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MDA-MB-231
Concentration: 0.025 μM; 0.05 μM; 0.1 μM
Incubation Time: 24 h
Result: Dose-dependently reduced colony-forming ability of MDA-MB-231 cells, with colony formation rates of 66.17% at 0.025 μM, 50.00% at 0.05 μM, and 33.46% at 0.1 μM.
Showed stronger inhibitory activity than chidamide (86.07% colony formation rate) at 0.1 μM.

Apoptosis Analysis[1]

Cell Line: MDA-MB-231
Concentration: 0.025 μM; 0.05 μM; 0.1 μM
Incubation Time: 48 h
Result: Dose-dependently increased the proportion of Annexin V-positive apoptotic cells.
Markedly elevated the proportion of apoptotic cells (Annexin V-positive, PI-positive/negative) compared to untreated control at 0.1 μM, with 21.16% of cells in the early apoptotic quadrant and 29.33% in the late apoptotic quadrant.

Cell Migration Assay [1]

Cell Line: MDA-MB-231
Concentration: 0.01 μM; 0.02 μM; 0.04 μM
Incubation Time: 24 h; 48 h
Result: Inhibited migration capacity at both 24 h and 48 h.
Reduced migration rates to 66.65% at 0.01 μM, 50.42% at 0.02 μM, and 30.99% at 0.04 μM after 48 h.
Showed stronger inhibitory activity than chidamide (51.69% migration rate at 48 h) at 0.04 μM.
Molekulargewicht

872.45

Formel

C47H47ClFN9O3S
CAS. Nr.
SMILES

CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(NCCCCCCNC5=CC(F)=CC=C5NC(C6=CC=C(C=C6)CNC(/C=C/C7=CC=CN=C7)=O)=O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 317 Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 3173117779-13-9Anticancer agent317Anticancer agent-317Apoptosisbreast cancertumor growthBRD4apoptosisMDA-MB-231 breast cancer cellscolony formationadhesioninvasionangiogenesismigrationInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Anticancer agent 317
Art. -Nr.:
HY-183302
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.